Literature DB >> 29766222

Cisplatin increases the number of enterochromaffin cells containing substance P in rat intestine.

Yusuke Obara1, Takuji Machida2, Yuho Takano1, Saki Shiga1, Asami Suzuki1, Naoya Hamaue3, Kenji Iizuka1, Masahiko Hirafuji1.   

Abstract

We previously reported that cisplatin potentiated ileal 5-hydroxytryptamine (5-HT) metabolism and caused pathological changes with an inflammatory response in the delayed phase (72 h) after administration to rats. In the present study, we further investigated the time-dependent effect of cisplatin on ileal 5-HT metabolism and the effects of combining cisplatin and anti-inflammatory drugs on ileal tryptophan hydroxylase expression and pica (the consumption of non-nutritive materials such as kaolin). Cyclooxygenase-2 (COX-2) expression was significantly increased at 24 h after cisplatin (5 mg/kg, intraperitoneal) administration. Cisplatin significantly increased ileal 5-HT content at 48 h after administration and the number of L-tryptophan hydroxylase-expressing cells (i.e., enterochromaffin cells) in the ileal mucosa within 24 h after administration. It also caused a significant increase in the number of substance P-expressing cells. Immunohistochemical double staining revealed that most of the enterochromaffin cells contained substance P. Neither daily treatment with dexamethasone (1 mg/kg, subcutaneous) nor meloxicam (3 mg/kg, subcutaneous), a selective COX-2 inhibitor, affected the cisplatin-induced increase in the number of enterochromaffin cells. Meloxicam had no effect on cisplatin-induced pica, although dexamethasone almost completely inhibited it. This study demonstrated that cisplatin administration induced COX-2 expression and increased the number of enterochromaffin cells in the acute phase (i.e., within 24 h). However, COX-2 expression in the ileum seems to have little direct effect on the mechanism of the induction of enterochromaffin cells and pica.

Entities:  

Keywords:  5-hydroxytryptamine; Cisplatin; Cyclooxygenase; Enterochromaffin cells; L-tryptophan hydroxylase; Substance P

Mesh:

Substances:

Year:  2018        PMID: 29766222     DOI: 10.1007/s00210-018-1493-5

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  29 in total

1.  Administration of olanzapine as an antiemetic agent changes glucose homeostasis in cisplatin-treated rats.

Authors:  Maiko Machida; Yuki Miyamura; Takuji Machida; Kinuko Koyama; Kenji Iizuka; Masahiko Hirafuji
Journal:  Biol Pharm Bull       Date:  2015       Impact factor: 2.233

Review 2.  Neuropharmacology of emesis and its relevance to anti-emetic therapy. Consensus and controversies.

Authors:  P L Andrews; R J Naylor; R A Joss
Journal:  Support Care Cancer       Date:  1998-05       Impact factor: 3.603

3.  The effects of different corticosteroids on the healing colon anastomosis and cecum in a rat model.

Authors:  T R Eubanks; J J Greenberg; P B Dobrin; F J Harford; R L Gamelli
Journal:  Am Surg       Date:  1997-03       Impact factor: 0.688

4.  Differential action of ondansetron and dexamethasone to modify cisplatin-induced acute and delayed kaolin consumption ("pica") in rats.

Authors:  John A Rudd; Kouichi Yamamoto; Atsushi Yamatodani; Noriaki Takeda
Journal:  Eur J Pharmacol       Date:  2002-11-01       Impact factor: 4.432

5.  Enterochromaffin cells as the endocrine source of gastrointestinal substance P.

Authors:  P Heitz; J M Polak; D M Timson; A G Pearse
Journal:  Histochemistry       Date:  1976-11-12

6.  Impact of an anti-inflammatory therapy and its withdrawal on the progression of experimental periodontitis in rats.

Authors:  Bruno César de Vasconcelos Gurgel; Poliana Mendes Duarte; Francisco H Nociti; Enilson A Sallum; Márcio Zaffalon Casati; Antonio Wilson Sallum; Sérgio de Toledo
Journal:  J Periodontol       Date:  2004-12       Impact factor: 6.993

7.  The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets.

Authors:  F D Tattersall; W Rycroft; M Cumberbatch; G Mason; S Tye; D J Williamson; J J Hale; S G Mills; P E Finke; M MacCoss; S Sadowski; E Ber; M Cascieri; R G Hill; D E MacIntyre; R J Hargreaves
Journal:  Neuropharmacology       Date:  2000-02-14       Impact factor: 5.250

8.  The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.

Authors:  Paul J Hesketh; Steven M Grunberg; Richard J Gralla; David G Warr; Fausto Roila; Ronald de Wit; Sant P Chawla; Alexandra D Carides; Juliana Ianus; Mary E Elmer; Judith K Evans; Klaus Beck; Scott Reines; Kevin J Horgan
Journal:  J Clin Oncol       Date:  2003-10-14       Impact factor: 44.544

Review 9.  Pharmacological aspects of anticancer drug-induced emesis with emphasis on serotonin release and vagal nerve activity.

Authors:  Masaru Minami; Toru Endo; Masahiko Hirafuji; Naoya Hamaue; Yanxia Liu; Tsutomu Hiroshige; Masahiro Nemoto; Hideya Saito; Mitsuhiro Yoshioka
Journal:  Pharmacol Ther       Date:  2003-08       Impact factor: 12.310

10.  Anti-inflammatory drugs ameliorate opposite enzymatic changes in ileal 5-hydroxytryptamine metabolism in the delayed phase after cisplatin administration to rats.

Authors:  Chuanxia Ju; Naoya Hamaue; Takuji Machida; Yanxia Liu; Kenji Iizuka; Yue Wang; Masaru Minami; Masahiko Hirafuji
Journal:  Eur J Pharmacol       Date:  2008-05-06       Impact factor: 4.432

View more
  2 in total

Review 1.  A Focus on Enterochromaffin Cells among the Enteroendocrine Cells: Localization, Morphology, and Role.

Authors:  Rita Rezzani; Caterina Franco; Lorenzo Franceschetti; Marzia Gianò; Gaia Favero
Journal:  Int J Mol Sci       Date:  2022-03-29       Impact factor: 5.923

Review 2.  Mechanisms of Nausea and Vomiting: Current Knowledge and Recent Advances in Intracellular Emetic Signaling Systems.

Authors:  Weixia Zhong; Omar Shahbaz; Garrett Teskey; Abrianna Beever; Nala Kachour; Vishwanath Venketaraman; Nissar A Darmani
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.